Gene Co-expression Network Analysis for Identifying Modules and Functionally Enriched Pathways in Vitiligo Disease: A Systems Biology Study.

Vitiligo is the most common cause of skin, hair, and oral depigmentation which is known as an autoimmune disorder. Genetic and environmental factors have important roles in the progression of the disease. Dysregulation of gene expression, like microRNAs (miRNA), may serve as major relevant factors. Several biological processes are involved in vitiligo disease and developing a comprehensive approach helps us to better understand the molecular mechanisms of disease. In this research, we describe how a weighted gene co-expression network analysis as a systems biology approach assists to define the primary gene modules, hub genes, and messenger RNA (mRNA)-miRNA regulatory network in vitiligo disease as the novel biomarkers. The results demonstrated a module with a high correlation with vitiligo state. Moreover, gene enrichment analysis showed that this module's genes were mostly involved in some biological activities including G protein-coupled receptors signaling pathway, lymphocyte chemotaxis, chemokine activity, neutrophil migration, granulocyte chemotaxis, etc. The co-expression network was constructed using top hub genes of the correlated module which are named as CXCL10, ARL9, AKR1B10, COX7B, RPL26, SPA17, NDUFAF2, RPF2, DAPL1, RPL34, CWC15, NDUFB3, RPL26L1, ACOT13, HSPB11, and NSA2. MicroRNAs prediction tool (miRWalk) revealed top miRNAs correlated with the interested module. Finally, a drug-target network was constructed which indicated interactions of some food and drug administration (FDA) approved drugs with hub genes. Our findings specified one important module and main hub genes which can be considered as novel biomarkers for vitiligo therapeutic purposes.

[1]  Z. Rezaei,et al.  Involvement of the Dysregulation of miR-23b-3p, miR-195-5p, miR-656-5p, and miR-340-5p in Trastuzumab Resistance of HER2-Positive Breast Cancer Cells and System Biology Approach to Predict Their Targets Involved in Resistance. , 2019, DNA and cell biology.

[2]  A. Bishnoi,et al.  Clinical and Molecular Aspects of Vitiligo Treatments , 2018, International journal of molecular sciences.

[3]  A. Pandya,et al.  Epidemiology of Vitiligo , 2018 .

[4]  F. Lin,et al.  Role of chemokines and the corresponding receptors in vitiligo: A pilot study , 2018, The Journal of dermatology.

[5]  U. Khan,et al.  T Lymphocytes and Autoimmunity. , 2018, International review of cell and molecular biology.

[6]  Hongwen Li,et al.  Altered expression of four miRNA (miR‐1238‐3p, miR‐202‐3p, miR‐630 and miR‐766‐3p) and their potential targets in peripheral blood from vitiligo patients , 2017, The Journal of dermatology.

[7]  J. Harris,et al.  Vitiligo Pathogenesis and Emerging Treatments. , 2017, Dermatologic clinics.

[8]  Seena K. Ajit,et al.  Regulation of proinflammatory genes by the circulating microRNA hsa-miR-939 , 2016, Scientific Reports.

[9]  W. Cao,et al.  Multiple region whole-exome sequencing reveals dramatically evolving intratumor genomic heterogeneity in esophageal squamous cell carcinoma , 2015, Oncogenesis.

[10]  M. Taghizadeh,et al.  Single Nucleotide Polymorphism rs 2476601 of PTPN22 Gene and Susceptibility to Rheumatoid Arthritis in Iranian Population. , 2015, Iranian journal of allergy, asthma, and immunology.

[11]  A. Antonelli,et al.  The role of the Th1 chemokine CXCL10 in vitiligo. , 2015, Annals of translational medicine.

[12]  S. Gurunathan,et al.  Oxidative stress and ROS metabolism via down-regulation of sirtuin 3 expression in Cmah-null mice affect hearing loss , 2015, Aging.

[13]  S. Moretti,et al.  Oxidative Stress and Immune System in Vitiligo and Thyroid Diseases , 2015, Oxidative medicine and cellular longevity.

[14]  N. Dang,et al.  Differential expression analysis of miRNA in peripheral blood mononuclear cells of patients with non‐segmental vitiligo , 2015, The Journal of dermatology.

[15]  C. Akdis,et al.  MicroRNA-146a alleviates chronic skin inflammation in atopic dermatitis through suppression of innate immune responses in keratinocytes. , 2014, The Journal of allergy and clinical immunology.

[16]  C. Hunter,et al.  CXCL10 Is Critical for the Progression and Maintenance of Depigmentation in a Mouse Model of Vitiligo , 2014, Science Translational Medicine.

[17]  Henry W. Lim,et al.  Serum miRNA expression profiles change in autoimmune vitiligo in mice , 2014, Experimental dermatology.

[18]  J. Richmond,et al.  Innate immune mechanisms in vitiligo: danger from within. , 2013, Current opinion in immunology.

[19]  C. Akdis,et al.  MicroRNAs: Essential players in the regulation of inflammation. , 2013, The Journal of allergy and clinical immunology.

[20]  C. Geisler,et al.  Allergic contact dermatitis induces upregulation of identical microRNAs in humans and mice , 2012, Contact dermatitis.

[21]  Chaodong Li,et al.  Silencing expression of ribosomal protein L26 and L29 by RNA interfering inhibits proliferation of human pancreatic cancer PANC-1 cells , 2012, Molecular and Cellular Biochemistry.

[22]  M. Picardo,et al.  Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference , 2012, Pigment cell & melanoma research.

[23]  Shanchun Guo,et al.  The emerging role of CXCL 10 in cancer ( Review ) , 2011 .

[24]  C. Melief,et al.  Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. , 2009, The Journal of investigative dermatology.

[25]  D. Bani,et al.  Keratinocyte dysfunction in vitiligo epidermis: cytokine microenvironment and correlation to keratinocyte apoptosis. , 2009, Histology and histopathology.

[26]  N. J. Gibbons,et al.  Methionine sulfoxide reductases A and B are deactivated by hydrogen peroxide (H2O2) in the epidermis of patients with vitiligo. , 2008, The Journal of investigative dermatology.

[27]  A. R. Gani,et al.  Association of catalase T/C exon 9 and glutathione peroxidase codon 200 polymorphisms in relation to their activities and oxidative stress with vitiligo susceptibility in Gujarat population. , 2007, Pigment cell research.

[28]  P. Janson,et al.  MicroRNAs: Novel Regulators Involved in the Pathogenesis of Psoriasis? , 2007, PloS one.

[29]  Yong Zhao,et al.  A developmental view of microRNA function. , 2007, Trends in biochemical sciences.

[30]  R. Spritz The genetics of generalized vitiligo and associated autoimmune diseases. , 2007, Pigment cell research.

[31]  M. Mahmoudi,et al.  Identification of hitherto undefined B-cell epitopes by antibodies in the sera of vitiligo patients using phage-display Peptide library. , 2003, Iranian journal of allergy, asthma, and immunology.

[32]  J. Naeyaert,et al.  Evidence for an autoimmune pathogenesis of vitiligo. , 2003, Pigment cell research.

[33]  P. Santamaria Cytokines and chemokines in autoimmune disease: an overview. , 2003, Advances in experimental medicine and biology.

[34]  N. Solvason,et al.  Chemokines in autoimmune diseases , 2000, Immunological reviews.

[35]  G. Ogg,et al.  High Frequency of Skin-homing Melanocyte-specific Cytotoxic T Lymphocytes in Autoimmune Vitiligo , 1998, The Journal of experimental medicine.

[36]  H. Furumoto,et al.  Successful Treatment of Vitiligo with a Sex Steroid‐Thyroid Hormone Mixture , 1995, The Journal of dermatology.

[37]  R. V. van Vollenhoven,et al.  Estrogen, progesterone, and testosterone: can they be used to treat autoimmune diseases? , 1994, Cleveland Clinic journal of medicine.

[38]  D. Sullivan,et al.  Testosterone-induced suppression of autoimmune disease in lacrimal tissue of a mouse model (NZB/NZW F1) of Sjögren's syndrome. , 1991, Investigative ophthalmology & visual science.